display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
billiary tract cancer - 1st line (L1)
billiary tract cancer - 1st line (L1)
durvalumab based treatment
durvalumab plus SoC TOPAZ-1

Study type: